Ensol Bioscience Inc. has been building ETONS(Ensol Trans-Omics Network System), a prediction system for toxic side effects by verifying the more efficient new drug candidate materials based on its core technology, KISDD(Knowledge-based In Silico Drug Discovery). KISDD is a "bio big data based'' search platform that scans for any new drug candidates for the cure of incurable diseases. Ensol’s main focused diseases are Degenerative Disc Disease (DDD), Osteoarthritis (OA) Disease, TripleNegative Breast Cancer (TNBC), Alzheimer’s Disease (AD), and Type 1 Diabetes (T1D). Ensol is now enlisted on KONEX and plans to move to KOSDAQ, a larger public stock exchange bourse in South Korea, for stockholder’s conveniences and company valuation increase.